Adc Therapeutics Ltd Stock News

Want to try an out-of-the-box approach? Tap four stocks, namely Eastside Distilling (EAST), AMC Entertainment (AMC), CuriosityStream (CURI) and ADC Therapeutics (ADCT).

ADCT faced the brunt of the FDA's new policy against rampant accelerated approvals. Despite positive data, Camidanlumab is not going to be in the market anytime soon.

Upgrades Janney Montgomery Scott upgraded the previous rating for First Bancshares Inc (NASDAQ:FBMS) from Neutral to Buy. First Bancshares earned $0.85 in the third quarter, compared to $0.76 in the y

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0

ADC Therapeutics SA (NYSE:ADCT ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Joe Camardo - Chief Medical Officer J

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc

Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m.

AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

On Vertex Pharmaceuticals' (VRTX) Q3 earnings call, investors' focus will likely be on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. Gravitas Education Holdings, Inc. (NASDAQ: GEHI) sh

The heavy selling pressure might have exhausted for ADC Therapeutics SA (ADCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street